Online tool encourages families to bone up on genetics

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute have developed a free, online assessment tool that allows individuals to enter their family medical history, and determine their risk for both cancer and coronary heart disease.

Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute have developed a free, online assessment tool that allows individuals to enter their family medical history, and determine their risk for both cancer and coronary heart disease.

Called Family HealthLink, the tool was created by the Clinical Cancer Genetics and Medical Genetics Programs. The survey takes approximately 15 minutes to complete and provides a printable risk assessment that can be used for discussion with a physician or genetic counselor.

“It is important that families take the time to discuss their health in order to better understand their risk for cancer and coronary heart disease and improve screening and prevention methods,” said Kevin Sweet, genetic counselor and director of the Family HealthLink project.

To access Family HealthLink, go to familyhealthlink.osumc.edu or call 1-888-329-1654 to reach the genetics programs by phone.

Recent Videos
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.